Did Getinge acquire Maquet?
Yes, Gilead Sciences successfully completed its acquisition of Arcellx, Inc. in April 2026. The transaction was valued at approximately $7.8 billion and gave Gilead full control of Arcellx’s investigational BCMA-directed CAR T-cell therapy, anito-cel, which is being developed for the treatment of multiple myeloma. By consolidating ownership and eliminating future profit-share and royalty obligations, Gilead aimed to streamline the clinical development process and integrate the therapy into its existing Kite Pharma division. This acquisition was a major strategic move for Gilead, intended to bolster its leadership in oncology and cell therapy and to accelerate the commercialization of potentially life-saving treatments for patients living with difficult-to-treat cancers.
Related FAQs
Givaudan SA operates with a worldwide workforce comprising approximately nineteen thousand four hundred employees across its global network of production facilities, creation centers, and commercial offices. Headquartered in Vernier, Switzerland, ...
Arjo operates as an independent, publicly traded company listed on Nasdaq Stockholm rather than a subsidiary owned by Getinge. Although Arjo historically served as Getinge's extended care business area following a 1995 acquisition, Getinge formall...